Every organ in the body receives oxygen from the lungs through red blood cells. To maintain a steady supply of oxygen, blood-forming stem cells must produce approximately 200 billion new red blood ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a ...

Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells and reversed diabetes in a preclinical study led by Weill Cornell ...

Mean corpuscular hemoglobin (MCH) is a measurement of the average amount of hemoglobin within a red blood cell. MCH that's lower or higher than normal may indicate you have a condition such as ...

Islet Transplantation with Blood Vessel Cells Shows Promise to Treat Type 1 Diabetes Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin ...

He’s got new blood. A Long Island hospital said it administered life-changing Lyfgenia gene therapy treatment and successfully wiped away sickle cell disease from a Laurelton man. Cohen Children ...

Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells and reversed diabetes in a preclinical study led by Weill Cornell ...

Their results ... Jan. 17, 2025 — A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from their surfaces ...

What Is Cord Blood Banking? Cord blood banking is a process of collecting potentially life-saving stem cells from the umbilical cord and placenta and storing them for future use. Stem cells are ...

Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense oligonucleotide for a rare type of blood cancer. The RNA-targeted ...

An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a rare blood cancer — achieving the efficacy goals of a Phase 3 study.